<DOC>
	<DOC>NCT01806896</DOC>
	<brief_summary>This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.</brief_summary>
	<brief_title>Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Must have a diagnosis of Huntington's Disease a CAG repeat expansion equal or great than 39 a Unified Huntington Disease Rating Scale (UHDRS) Total Motor Score equal or greater than 5 and less than 60 a UHDRS Total Functional Capacity equal or greater than 9 Subjects with evidence or history of severe acute or chronic medical condition or laboratory abnormality, or significant neurological disorder other than HD. Treatment with any antipsychotic medication within 5 weeks of enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>